Saturday, October 3, 2026

Coffee Futures Went Up By Over 14% In The Last 21 Sessions

ViaNews Editorial Team

November 30, 2023

Coffee Futures Went Up By Over 14% In The Last 21 Sessions

(VIANEWS) - Coffee (KC) has been up by 14.08% for the last 21 sessions. At 13:50 EST on Thursday, 30 November, Coffee (KC) is $175.85.

Volume

Today's last reported volume for Coffee is 2444, 87.97% below its average volume of 20325.65.

Volatility

Coffee's last week, last month's, and last quarter's current intraday variation average was a negative 5.26%, a negative 2.22%, and a positive 2.03%, respectively.

Coffee's highest amplitude of average volatility was 5.26% (last week), 3.32% (last month), and 2.03% (last quarter), respectively.

Commodity Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Coffee's commodity is considered to be oversold (<=20).

News about

  • Crude oil Tuesday ralies to snap four-day losing streak, WTI tests $77.00. According to FXStreet on Tuesday, 28 November, "With current OPEC production caps not enough to stem the tide of declining Crude Oil prices, energy markets will be paying extra attention to the global oil cartel's conversations at the upcoming meeting, where production quotas are sure to be the primary topic of conversation.", "West Texas Intermediary (WTI) Crude Oil caught a bid in a broad-market risk bid as investor sentiment improved across the board."

More news about Coffee (KC).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,329 source documents archived
Query this data → isubstrate.com